University of Groningen Early Conversion to Prednisolone/Everolimus as an Alternative Weaning Regimen Associates With Beneficial Renal Transplant Histology and Function Bemelman,

Citation for published version (APA): Bemelman, F. J., de Fijter, J. W., Kers, J., Meyer, C., Peters-Sengers, H., de Maar, E. F., ... van der Heide, J. J. H. (2017). Early Conversion to Prednisolone/Everolimus as an Alternative Weaning Regimen Associates With Beneficial Renal Transplant Histology and Function: The Randomized-Controlled MECANO Trial. American Journal of Transplantation, 17(4), 1020-1030. https://doi.org/10.1111/ajt.14048

[1]  David W. Johnson,et al.  Mammalian Target of Rapamycin Inhibitors and Clinical Outcomes in Adult Kidney Transplant Recipients. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[2]  F. Lehner,et al.  Five‐Year Outcomes in Kidney Transplant Patients Converted From Cyclosporine to Everolimus: The Randomized ZEUS Study , 2015, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  V. Mas,et al.  Impact of Calcineurin‐Inhibitor Conversion to mTOR Inhibitor on Renal Allograft Function in a Prednisone‐Free Regimen , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[4]  R. Starling,et al.  Cardiac allograft vasculopathy by intravascular ultrasound in heart transplant patients: substudy from the Everolimus versus mycophenolate mofetil randomized, multicenter trial. , 2013, JACC. Heart failure.

[5]  A. Kukla,et al.  Calcineurin Inhibitor Nephrotoxicity: A Review and Perspective of the Evidence , 2013, American Journal of Nephrology.

[6]  A. Rule,et al.  MDRD Versus CKD-EPI Equation to Estimate Glomerular Filtration Rate in Kidney Transplant Recipients , 2013, Transplantation.

[7]  E. Lerut,et al.  Chronic Histological Damage in Early Indication Biopsies Is an Independent Risk Factor for Late Renal Allograft Failure , 2013, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[8]  H. Fagertun,et al.  Improved Renal Function After Early Conversion From a Calcineurin Inhibitor to Everolimus: a Randomized Trial in Kidney Transplantation , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[9]  K. Budde,et al.  Donor‐Specific HLA Antibodies in a Cohort Comparing Everolimus With Cyclosporine After Kidney Transplantation , 2012, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[10]  J. Boggia,et al.  Delayed mTOR Inhibition with Low Dose of Everolimus Reduces TGFβ Expression, Attenuates Proteinuria and Renal Damage in the Renal Mass Reduction Model , 2012, PloS one.

[11]  C. Elie,et al.  Specificity of Histological Markers of Long‐Term CNI Nephrotoxicity in Kidney‐Transplant Recipients Under Low‐Dose Cyclosporine Therapy , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[12]  A. Sharif,et al.  Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. , 2011, Journal of the American Society of Nephrology : JASN.

[13]  A. Jardine,et al.  Conversion of Long-Term Kidney Transplant Recipients From Calcineurin Inhibitor Therapy to Everolimus: A Randomized, Multicenter, 24-Month Study , 2011, Transplantation.

[14]  Mohammad F Huque,et al.  Method of balanced adjustment in testing co‐primary endpoints , 2010, Statistics in medicine.

[15]  J. Klempnauer,et al.  Acute rejection in low‐toxicity regimens: clinical impact and risk factors in the Symphony study , 2010, Clinical transplantation.

[16]  J. D. de Fijter,et al.  Individualizing calcineurin inhibitor therapy in renal transplantation--current limitations and perspectives. , 2010, Current pharmaceutical design.

[17]  E. Lerut,et al.  Localization, Etiology and Impact of Calcium Phosphate Deposits in Renal Allografts , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[18]  J. J. Homan van der Heide,et al.  Minimization of Maintenance Immunosuppression Early After Renal Transplantation: An Interim Analysis , 2009, Transplantation.

[19]  P. Halloran,et al.  Calcineurin Inhibitor Minimization in the Symphony Study: Observational Results 3 Years after Transplantation , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[20]  G. Jhangri,et al.  Scoring Total Inflammation Is Superior to the Current Banff Inflammation Score in Predicting Outcome and the Degree of Molecular Disturbance in Renal Allografts , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[21]  F. Oppenheimer,et al.  The pharmacokinetics of mycophenolate mofetil in renal transplant recipients receiving standard-dose or low-dose cyclosporine, low-dose tacrolimus or low-dose sirolimus: the Symphony pharmacokinetic substudy. , 2009, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[22]  Minnie Sarwal,et al.  Calcineurin Inhibitor Nephrotoxicity , 2012 .

[23]  F. Schena,et al.  Conversion From Calcineurin Inhibitors to Sirolimus Maintenance Therapy in Renal Allograft Recipients: 24-Month Efficacy and Safety Results From the CONVERT Trial , 2009, Transplantation.

[24]  P. Halloran,et al.  Reduced exposure to calcineurin inhibitors in renal transplantation. , 2007, The New England journal of medicine.

[25]  E. Lerut,et al.  Tacrolimus Exposure and Evolution of Renal Allograft Histology in the First Year After Transplantation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[26]  B. Nashan,et al.  Cyclosporine Sparing with Mycophenolate Mofetil, Daclizumab and Corticosteroids in Renal Allograft Recipients: The CAESAR Study , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[27]  J. D. de Fijter,et al.  No difference in degree of interstitial Sirius red-stained area in serial biopsies from area under concentration-over-time curves-guided cyclosporine versus tacrolimus-treated renal transplant recipients at one year. , 2005, Journal of the American Society of Nephrology : JASN.

[28]  R. Oberbauer.  Calcineurin Inhibitor Withdrawal from Sirolimus‐Based Therapy in Kidney Transplantation: A Systematic Review of Randomized Trials , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[29]  Raimund Margreiter,et al.  Everolimus (Certican) 12-Month Safety and Efficacy Versus Mycophenolate Mofetil in de Novo Renal Transplant Recipients , 2004, Transplantation.

[30]  Lars Pape,et al.  Computer-assisted quantification of fibrosis in chronic allograft nephropaty by picosirius red-staining: a new tool for predicting long-term graft function1 , 2003, Transplantation.

[31]  B. Nashan,et al.  MULTICENTER TRIAL EXPLORING CALCINEURIN INHIBITORS AVOIDANCE IN RENAL TRANSPLANTATION , 2001, Transplantation.